Press release
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio
DelveInsight's "Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Liver Fibrosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Liver Fibrosis therapies. Additionally, we cover the landscape of Liver Fibrosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Liver Fibrosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Liver Fibrosis space.
To Know in detail about the Liver Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Fibrosis Market Forecast [https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Liver Fibrosis Market Report:
*
The Liver Fibrosis market size was valued ~USD 1,800 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
*
In December 2025, Galmed announced the grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for the treatment of MASH. The newly issued patent in South Korea complements previously granted patents in the United States, Europe, Canada, and other regions, with the U.S. patent set to expire in July 2042. Aramchol, a first-in-class, Phase 3-ready drug candidate, has demonstrated significant fibrosis improvement in advanced clinical trials.
*
In Sept 2025, Echosens announced that the FDA's Center for Drug Evaluation and Research (CDER) has accepted its Letter of Intent to qualify Liver Stiffness Measurement using FibroScan Registered as a surrogate endpoint in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
*
In August 2025, Madrigal Pharmaceuticals announced that the European Commission has granted conditional marketing authorization for Rezdiffra (resmetirom) to treat adults with noncirrhotic MASH and moderate to advanced liver fibrosis. With this approval, Rezdiffra becomes the first and only therapy for MASH authorized in the EU.
*
In May 2025, Novo Nordisk has announced that it will share new data from its metabolic and cardiovascular health portfolio at the 32nd European Congress on Obesity (ECO), taking place from May 11-14, 2025. The presentations will feature real-world evidence studies on semaglutide, further analyses from the SELECT cardiovascular outcomes trial, and results from part 1 of the Phase 3 ESSENCE trial for metabolic dysfunction-associated steatohepatitis (MASH).
*
In April 2025, Enrollment has been finalized for the Phase 3 NATiV3 clinical trial (NCT04849728), which is evaluating lanifibranor in individuals with metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis. According to the developer, Inventiva, if the results are favorable, the top-line data from this global study could support regulatory approval submissions for lanifibranor.
*
In March 2025, According to two-year data from the Phase 3 MAESTRO-NAFLD-1 clinical trial (NCT04197479), long-term treatment with Rezdiffra (resmetirom) has been shown to reduce liver scarring in most individuals with compensated cirrhosis-irreversible scarring in a still-functioning liver-caused by metabolic dysfunction-associated steatohepatitis (MASH). This finding was recently revealed by Madrigal Pharmaceuticals, the developer of the therapy.
*
In March 2025, Akero Therapeutics' experimental therapy efruxifermin has shown the ability to reverse compensated cirrhosis-permanent liver scarring with preserved function-in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. These top-line results come from the Phase 2b SYMMETRY clinical trial (NCT05039450) and were described by the company as both "unprecedented" and statistically significant in a recent press release. The findings align with previous Phase 2b HARMONY trial (NCT04767529) data, which demonstrated that efruxifermin reduced liver fibrosis in patients with MASH who had not yet developed cirrhosis.
*
In January 2025, Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced promising topline results from two clinical trials of lixudebart (ALE.F02), a monoclonal antibody designed to reverse organ fibrosis.
*
In January 2025, Akero Therapeutics has released preliminary topline results from its Phase IIb SYMMETRY study, evaluating efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial included adult participants with the condition. The primary efficacy endpoint measured the proportion of patients achieving at least a one-stage fibrosis improvement by week 36 without MASH progression.
*
In November 2024, Scottish biopharmaceutical firm Resolution Therapeutics secured approval from Spain's Agency of Medicines and Medical Products (AEMPS) to extend its Phase I/II EMERALD trial of RTX001, a regenerative macrophage therapy, into Spain. RTX001, the company's flagship product, is an engineered autologous regenerative macrophage therapy designed for individuals with end-stage liver disease.
*
In November 2024, Novo Nordisk announced favorable results from the first part of the ESSENCE trial, evaluating semaglutide 2.4mg for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
*
In 2023, the US Liver Fibrosis Treatment Market was valued at around USD 1,300 million and is expected to grow with the introduction of emerging therapies.
*
In 2023, the Liver Fibrosis Treatment Market Size across the EU4 and the UK was estimated at around USD 400 million, accounting for approximately 23% of the total market revenue in the 7MM.
*
In 2023, Germany led the Liver Fibrosis Treatment Market within the EU4 and the UK, contributing approximately USD 120 million. Italy ranked second with around USD 95 million, followed by the UK at roughly USD 75 million.
*
In 2023, Japan's Liver Fibrosis Treatment Market was valued at approximately USD 80 million and is expected to grow throughout the forecast period (2025-2034).
*
Projections indicate that REZDIFFRA (resmetirom) could reach an estimated market value of around USD 2,500 million in the 7MM by 2034.
*
DelveInsight's epidemiology model estimates that in 2023, around 8 million diagnosed prevalent cases of liver fibrosis were recorded across the 7MM, with numbers expected to rise by 2034.
*
In 2023, the US had the highest number of liver fibrosis cases among the 7MM, with around 4 million cases, projected to increase by 2034.
*
In 2023, Germany recorded the highest number of liver fibrosis cases among the EU4 and the UK, with approximately 770,000 cases. Italy and France followed with around 620,000 and 520,000 cases, respectively, while Spain had the lowest, with approximately 360,000 cases.
*
In Japan, during 2023, MASH/NASH cases were classified by severity into F0, F1, F2, F3, and F4 stages. The F1 stage had the highest prevalence, with approximately 240,000 cases, whereas the F4 stage had the lowest, with around 35,000 cases.
*
Key Liver Fibrosis Companies: Madrigal Pharmaceuticals, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
*
Key Liver Fibrosis Therapies: REZDIFFRA (resmetirom), Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
*
The Liver Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.
*
According to DelveInsight's assessment, the estimated total number of diagnosed prevalent cases of liver fibrosis in the 7MM was approximately 19 million in 2023.
*
In 2023, the United States recorded the highest number of diagnosed prevalent cases of liver fibrosis, with 9 million cases, and this figure is expected to increase in the future.
*
In 2023, Germany had the highest number of diagnosed prevalent cases of liver fibrosis among European countries, followed by Italy, while Spain had the fewest cases.
*
In 2023, Japan had around 2 million diagnosed prevalent cases of liver fibrosis, representing approximately 12% of the total cases in the 7MM.
*
In the US, individuals in the F1 stage of NASH were most impacted by liver fibrosis, with approximately 3 million cases reported in 2023, based on severity-specific diagnosed prevalent cases.
*
In 2023, the total diagnosed prevalent cases of NASH-related liver fibrosis in the EU4 and the UK were approximately 1 million.
Liver Fibrosis Overview
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, in the liver, resulting from chronic liver damage. It occurs when the liver attempts to repair itself after prolonged inflammation or injury caused by conditions such as hepatitis, alcohol abuse, or fatty liver disease. Over time, fibrosis can lead to the scarring of liver tissue, potentially progressing to cirrhosis, which impairs liver function. Early-stage fibrosis is often reversible if the underlying cause is treated, but advanced stages may cause significant liver damage.
Get a Free sample for the Liver Fibrosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/liver-fibrosis-market [https://www.delveinsight.com/report-store/liver-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Liver Fibrosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Liver Fibrosis Epidemiology Segmentation:
The Liver Fibrosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Liver Fibrosis
*
Prevalent Cases of Liver Fibrosis by severity
*
Gender-specific Prevalence of Liver Fibrosis
*
Diagnosed Cases of Episodic and Chronic Liver Fibrosis
Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Liver Fibrosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Fibrosis market or expected to get launched during the study period. The analysis covers Liver Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on
market share.
The report also covers the Liver Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Liver Fibrosis Therapies and Key Companies
*
REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
*
Efruxifermin (EFX): Akero Therapeutics
*
Denifanstat (TVB-2640): Sagimet Biosciences
*
Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
*
Pegozafermin (BIO89-100): 89bio
*
Hydronidone capsules: Beijing Continent Pharmaceutical
*
Simtuzumab: Gilead Sciences
*
Aramchol: Galmed R&D
*
Rencofilstat: Hepion Pharmaceuticals
*
oltipraz: HK inno.N Corporation
*
IDN-6556: Conatus Pharmaceuticals
*
ZED1227: Dr. Falk Pharma GmbH
*
interferon gamma-1b: InterMune
*
BMS-986263: Bristol-Myers Squibb
*
peginterferon alfa-2b (SCH 54031): Merck Sharp & Dohme LLC
*
Efruxifermin: Akero Therapeutics, Inc
*
PF-06865571: Pfizer
*
Zibotentan + dapagliflozin: AstraZeneca
Discover more about therapies set to grab major Liver Fibrosis market share @ Liver Fibrosis Treatment Landscape [https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Liver Fibrosis Market Drivers
*
Rising Prevalence of Chronic Liver Diseases
*
Advancements in Diagnostic Techniques
*
Ongoing Drug Development
*
Awareness Programs
*
Government Initiatives
Liver Fibrosis Market Barriers
*
High Treatment Costs
*
Lack of Approved Therapies
*
Slow Diagnosis in Early Stages
*
Regulatory Challenges
*
Patient Adherence Issues
Scope of the Liver Fibrosis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Liver Fibrosis Companies: Madrigal Pharmaceuticals, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
*
Key Liver Fibrosis Therapies: REZDIFFRA (resmetirom), Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
*
Liver Fibrosis Therapeutic Assessment: Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
*
Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Liver Fibrosis Unmet Needs, KOL's views, Analyst's views, Liver Fibrosis Market Access and Reimbursement
To know more about Liver Fibrosis companies working in the treatment market, visit @ Liver Fibrosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Liver Fibrosis Market Report Introduction
2. Executive Summary for Liver Fibrosis
3. SWOT analysis of Liver Fibrosis
4. Liver Fibrosis Patient Share (%) Overview at a Glance
5. Liver Fibrosis Market Overview at a Glance
6. Liver Fibrosis Disease Background and Overview
7. Liver Fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Liver Fibrosis
9. Liver Fibrosis Current Treatment and Medical Practices
10. Liver Fibrosis Unmet Needs
11. Liver Fibrosis Emerging Therapies
12. Liver Fibrosis Market Outlook
13. Country-Wise Liver Fibrosis Market Analysis (2020-2034)
14. Liver Fibrosis Market Access and Reimbursement of Therapies
15. Liver Fibrosis Market Drivers
16. Liver Fibrosis Market Barriers
17. Liver Fibrosis Appendix
18. Liver Fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liver-fibrosis-market-expected-to-gain-momentum-through-2034-according-to-delveinsight-madrigal-pharma-akero-therapeutics-sagimet-biosciences-boehringer-ingelheim-zealand-pharma-89bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio here
News-ID: 4312042 • Views: …
More Releases from ABNewswire
What are the two types of push button switches?
In industrial automation, machinery, home appliances, and control systems, push button [https://www.onpowbutton.com/push-button-switch/] switches are among the most common and essential control components. Although there are many designs on the market, push buttons can essentially be divided into two primary types based on structure and operating logic: Momentary and Latching
Understanding the differences between them helps engineers, buyers, and equipment manufacturers make better selections and improve equipment stability and safety
Image: https://www.onpowbutton.com/uploads/35.png [https://www.onpowbutton.com/]
1.…
Why Using Allyking as The Shrimp Box Material?
When it comes to frozen seafood packaging-especially shrimp boxes-the choice of Paper [https://www.sure-paper.com/paper/] board directly determines your product's safety, performance, and shelf appeal. Among many packaging materials on the market, Allyking PE-Coated paperboard from APP has become a preferred choice for shrimp processors, seafood exporters, and food packaging converters.
In this article, we explain why Allyking is widely used for shrimp boxes, its unique features, and its performance advantages in frozen…
What is SOI? Industry Trends and Best Practices
SOI is the abbreviation for Silicon-On-Insulator. Literally, it means "silicon on an insulator." In practice, the structure is that there is an ultra-thin insulating layer, such as SiO, on top of the silicon wafer, and then a thin silicon layer is formed on top of this insulating layer. This structure separates the active silicon layer from the silicon substrate. In a traditional silicon process, however, the chip is formed directly…
Why one needs to choose Android Tap-to-Pay Tablet for any business?
The Rise of NFC Tap-to-Pay Tablets: Trends and Advantages Shaping the Future of Payments
In a world increasingly defined by digital transformation, NFC (Near Field Communication) technology has emerged as a cornerstone of modern payment systems. Tap-to-pay solutions, particularly those integrated into tablets, are revolutionizing how businesses accept payments, offering convenience, security, and flexibility. Let's explore the evolving trends and key advantages driving the adoption of NFC tap-to-pay tablets.
The Evolution and…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
